Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial

AIMS: The direct renin inhibitor, aliskiren, is known to reduce plasma renin activity (PRA), but whether the efficacy of aliskiren varies based on an individual’s baseline PRA in patients hospitalized for heart failure (HF) is presently unknown. We characterized the prognostic value of PRA and deter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Heart Fail
Main Authors: Vaduganathan, Muthiah, Cheema, Baljash, Cleveland, Erin, Sankar, Kamya, Subacius, Haris, Fonarow, Gregg C., Solomon, Scott D., Lewis, Eldrin F., Greene, Stephen J., Maggioni, Aldo P., Böhm, Michael, Zannad, Faiez, Butler, Javed, Gheorghiade, Mihai
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676477/
https://ncbi.nlm.nih.gov/pubmed/29143416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.973
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados